Engineered Human Hepatocyte Organoids Enable CRISPR-Based Target Discovery and Drug Screening for Steatosis

The authors used human fetal hepatocyte organoids to model the first stage of nonalcoholic fatty liver disease, steatosis, representing three different triggers: free fatty acid loading, interindividual genetic variability, and monogenic lipid disorders.